Fortitude Advisory Group’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Fortitude Advisory Group’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-265	Closed	–	–	1440
2022 Q1	$0	Hold	265	–	–	﹤0.01%	1627
2021 Q4	$1K	Buy	+265	New	+$1.08K	﹤0.01%	1529

Other funds holding KLDO

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fortitude Advisory Group's KLDO Position: Q2 2022 in Review

Fortitude Advisory Group sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 265 shares.

Fortitude Advisory Group first reported a position in KLDO in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

Fortitude Advisory Group reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Fortitude Advisory Group sold 265 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022.
Fortitude Advisory Group first reported a position in Kaleido Biosciences, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
Fortitude Advisory Group's Kaleido Biosciences, Inc. Common Stock position peaked at $1K in Q4 2021.
3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.